The biological and clinical importance of cytogenetic analysis in myelodysplastic syndrome (MDS) and in acute myeloid leukemia (AML) is being increasingly recognized. Recently, cytogenetic similarities were noted between elderly de novo AML and secondary AML, suggesting common etiopathogenetic mechanisms. In the present study we analyzed the cytogenetic similarities between patients with AML of different age and patients with MDS consecutively diagnosed during a 5-year period at a single, primary referral, hematologic center. Of 246 patients aged Ͻ86 years, 195 (80%) had a cytogenetic study at diagnosis. Informative metaphases were obtained in 182 cases (93%), including 17 (9.3%) with secondary MDS/AML. Patients were classified according to FAB criteria and were subdivided into four groups: (1) 'early MDS': 42 patients with MDS of FAB subtypes other than refractory anemia with excess of blasts (RAEB) or RAEB in transformation (RAEB-T); (2) 'late MDS': 35 patients with RAEB and RAEB-T; (3) 'old AML': 48 patients with AML aged 65 to 85 years; (4) 'young AML': 57 patients with AML aged Ͻ65 years. Results showed that 'late MDS' and 'old AML' had striking cytogenetic similarities both in the frequency of normal karyotypes (31% and 27%), single abnormalities (14% and 13%), double abnormalities (17% and 14%), complex karyotypes (37% and 46%), and numerical abnormalities (89% and 93%), as well as in the frequency of rearrangements involving chromosome 5 (20% and 31%) and 7 (27% and 27%). The only difference between the two groups was found in the median number of chromosomes involved in complex karyotypes (5 vs 8; P = 0.03). 'Early MDS' had significantly less complex karyotypes (21%; P Ͻ 0.05), but its cytogenetic features resembled otherwise those of 'late MDS' and 'old AML', and any significant difference disappeared when patients with chronic myelomonocytic leukemia (CMML) were excluded. CMML markedly differed from other MDS subtypes in the frequency of normal (57%) and of complex karyotypes (6%). Secondary MDS/AML and AML with trilineage dysplasia shared the same cytogenetic features of 'late MDS' and 'old AML'. 'Young AML' strikingly differed from all other groups, particularly in the higher frequency of balanced translocations (29%; P Ͻ 0.001) and single karyotype abnormalities (32%; P Ͻ 0.02), and in the lower frequency of complex karyotypes (19%; P Ͻ 0.01) and of chromosome 5 (2%; P Ͻ 0.001) and 7 (9%; P Ͻ 0.01) involvement. We conclude that in a population-based series of patients, the cytogenetic profile of MDS, particularly of RAEB/RAEB-T, was nearly identical to that of elderly patients with AML both in the frequency and in the type of chromosomal abnormalities. These results support the possibility that MDS and AML of elderly patients may represent the same disease seen at different stages of evolution. Leukemia (2000) 14, 636-641.
Introduction
The role of cytogenetic analysis in myelodysplastic syndrome Correspondence: G Rossi, Sezione Ematologia, Spedali Civili, p le Spedali Civili, 1, 25100 Brescia, Italy; Fax: +390 303 700 852 Received 3 June 1999; accepted 6 October 1999 (MDS) and in acute myeloid leukemia (AML) has emerged both as an independent prognostic indicator. [1] [2] [3] [4] [5] and as a tool for the identification of distinct disease categories, with specific etiopathogenetic mechanisms. 6, 7 Among de novo AML, distinct patterns of karyotype abnormalities are characteristic of different age groups. In younger patients simple aberrations, particularly disease-specific balanced translocations, are more frequent, their chromosomal breakpoints are highly conserved from case to case and they often give rise to chimeric fusion genes which may be directly involved in the pathogenesis of leukemia. [8] [9] [10] On the other hand, in older patients, balanced translocations are rare and complex karyotype aberrations predominate, with gain and/or loss of multiple chromosomal regions. 11 Also, age-related heterogeneity has been noted in AML with respect to differentiation of the stem cells involved by leukemia, which are more immature in AML of the elderly. 12 Recently, striking cytogenetic similarities have been noted between AML arising as de novo in elderly individuals, and AML or MDS developing after chemotherapy, particularly with alkylating agents, or after occupational exposure, suggesting a biologic relationship between de novo AML of elderly patients and secondary AML. 13 In the present study, we have analyzed the cytogenetic patterns of a single-center, population-based series of patients with AML or MDS. The results show that de novo AML of elderly individuals also has striking cytogenetic similarity with de novo MDS, particularly with their more advanced forms, refractory anemia with excess of blasts (RAEB) and RAEB in transformation (RAEB-T).
Materials and methods
A diagnosis of AML or MDS was made in 246 consecutive adult patients, aged 19-86 years, seen over a 5-year period at a hematologic primary referral center. Diagnosis and classification of cases was made according to FAB criteria. 14, 15 Cytogenetic analysis of cells obtained by marrow aspiration was performed in 80% of patients (195/246) using standard cytogenetic techniques. Marrow cells were collected in heparin (10/15 UI/ml) and placed in RPMI 1640 with 40% fetal calf serum at a concentration of 2 × 10 6 nucleated cells per ml. The cultures were incubated overnight at 37°C (approximately 24 h). No direct preparations were used. No mitotic stimulants were used. Standard harvesting procedure were utilized. Colcemid (0.01 mg/ml) was added to the cultures for 15 min. For the hypotonic treatment 0.075 M KCl was utilized for 10 min at 37°C. The fixation procedure consisted of three changes of 3:1 absolute methanol:glacial acetic acid solution with 10 min waiting period between each change. Air-dry slide preparations were made using wet slides at room temperature. Chromosomes were Q banded using quinacrine fluorescence (QFQ banding). The slides for QFQ banding 637 were placed in quinacrine 0.05% dilution in distilled water for 30 min and then washed in McIlvaine buffer pH 7.0. Whenever possible at least 20 metaphases were analyzed, both for structural and numerical chromosomal abnormalities. Karyotypes were assigned according to the recommendations of the International System for Human Cytogenetic Nomenclature (ISCN). 16 The observation of a minimum of two mitoses with an identical structural rearrangement or extra-chromosomes or three cells with the same missing chromosome was considered evidence for the existence of an abnormal clone.
Evaluable metaphases were obtained in 93% of cases (182/195), ie in 74% of all consecutive patients. Karyotypes were classified in four subgroups according to whether they showed no abnormalities in a minimum of 10 metaphases, a single chromosomal abnormality (one deletion/addition or one reciprocal translocation), two abnormalities, or a complex karyotype, ie three or more abnormalities, respectively.
Patients with evaluable metaphases were subdivided according to age and FAB criteria into the following four groups: (1) 'early MDS' (42 cases): patients with refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), chronic myelomonocytic leukemia (CMML); (2) 'late MDS' (35 cases): patients with RAEB or RAEB-T; (3) 'old AML' (48 cases): patients with AML aged 65 to 85; (4) 'young AML' (57 cases): patients with AML aged Ͻ65 years.
There were seven of 77 patients (9%) who had MDS diagnosed after a history of chemoradiotherapy for other cancers, three in 'early MDS' and four in 'late MDS', respectively. At AML diagnosis, 10 of 105 patients (9.5%) had a history of previous MDS or myeloproliferative disorders and/or of previous chemoradiotherapy, six in 'young AML' and four in 'old AML', respectively. In 20 patients with AML, morphological features at diagnosis showed dysplastic features both in erythroid, myeloid and megakaryocytic lineage. These cases were defined AML with trilineage dysplasia according to FAB criteria as described by Brito-Babapulle et al. 17 
Statistical analysis
The clinical and cytogenetic features of the four subgroups were analyzed and compared using BMDP software. Pearson's Chi-squared analysis, with Yates' correction when appropriate, and the two-sided Student's t-test were used for the comparisons between groups. For each comparison, the subgroups analyzed were specified in the text and/or in the tables. Survival probabilities were calculated with the method of Kaplan-Meyer and compared using Mantel-Cox analysis.
Results

Clinical features
The clinical features of the four groups of patients are shown in Table 1 . 'Early MDS' and 'late MDS' significantly differed in their hematologic features and in median survival (P = 0.0027). 'Old AML' and 'young AML' had similar hematologic features, except for FAB M3 frequency. However, median survival was significantly shorter in 'old AML' (P Ͻ 0.001). 'Late MDS' patients were significantly younger (P = 0.0002), and survived longer than 'old AML' patients (P = 0.0002).
Leukemia
Karyotypes
Normal karyotypes were obtained in 62 out of 182 patients (34%). Their median number of metaphases analyzed was 18 (range [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . A single karyotype abnormality was found in 38 cases (21%), a double abnormality in 27 cases (15%) and a complex karyotype in 55 cases (30%).
The frequency of the different types of karyotype abnormality in the four groups is shown in Figure 1 . 'Late MDS' and 'old AML' had a very similar frequency of different karyotype abnormalities. Compared to them, 'early MDS' had significantly fewer complex karyotypes (P Ͻ 0.05). However, as shown in Table 2 , when 14 patients with CMML were excluded from the 'early MDS' group, the pattern of karyotype aberrations of 'early MDS' did not show any more significant difference compared to 'late MDS' or 'old AML'. On the other hand, 'young AML' had a clearly distinct pattern of abnormal karyotypes compared to 'late MDS/old AML', with significantly more single karyotype abnormalities (P Ͻ 0.02) and fewer complex abnormalities (P Ͻ 0.01).
Karyotype abnormalities were similar among FAB subgroups, with the exception of FAB M3 among AML patients, and of CMML among 'early MDS' patients, in which the frequency of double or complex abnormalities was 6%, significantly lower than in other 'early MDS' patients (38%) (P Ͻ 0.01) ( Table 2) .
As shown in Table 3 , the median number of chromosomes involved in complex karyotypes differed among the four subgroups. It significantly increased from 'early MDS' (three, range 3-6) to 'late MDS' (five, range 3-10), and also from 'late MDS' to 'old AML', which had a median of eight chromosomes involved (range 3-16) (P = 0.03, compared to 'late MDS').
The influence of increasing age on the frequency of the different karyotype abnormalities is summarized in Table 4 . In patients with 'early MDS' and 'late MDS' analysis of younger age groups was hindered by the few patients aged less than 55 years. Nevertheless the pattern of karyotype abnormalities did not change in different age groups. On the other hand, in patients with 'young AML' there was a trend towards a decrease of single abnormalities and an increase of complex karyotypes with increasing age. Moreover the median number of chromosomes involved in complex karyotypes remained constant in patients with MDS, whereas in patients with AML, it showed a progressive increase with age.
Cytogenetic abnormalities
As far as the type of cytogenetic abnormality, numerical aberrations largely outweighed reciprocal translocations. Of 351 abnormalities, additions/deletions occurred in 311 cases (88.6%) and reciprocal translocations in 40 cases (11.4%). Reciprocal translocations were typically found in 'young AML'. In this group, their frequency was significantly higher (19 of 76: 29%), than in the other groups (21 of 275: 7.6%; P Ͻ 0.0001) ( Table 5 ).
Chromosomes
The involvement of specific chromosomes in the different cytogenetic abnormalities was similar between MDS and 'old AML'. Chromosomes 5, 7, and 8 were involved in more than 20% of cases, and chromosomes 3, 12, and 17 in over 10% 
Figure 1
Relative frequency of the different types of karyotype abnormality among the four different groups considered. NN, normal karyotype; single, single karyotype abnormality; double, two karyotype abnormalities; complex, three or more karyotype abnormalities. of cases. On the other hand, 'young AML' markedly differed from other groups, since chromosomes involved in over 10% of cases were 6, 8, 15, and 17. Chromosome 8 involvement occurred predominantly as trisomy 8 in all groups, whereas chromosome 17 showed partial or complete deletion in most patients with MDS or 'old AML', as opposed to balanced translocation with chromosome 15, in patients with 'young AML', who had promyelocytic leukemia. Noteworthy, 5−/del (5q) and 7−/del (7q) were typically found both in 'early MDS' and 'late MDS' and in 'old AML', whereas they occurred rarely in 'young AML' ( Table 6 ). The median age of patients with abnormalities of chromosome 5 and 7 was 68.5 (range 64-86) and 67 (range 46-85), respectively. 
Secondary MDS/AML and AML with trilineage dysplasia
Secondary MDS/AML was diagnosed in 17 patients, accounting for 9.3% of the total number of cases. When analyzed separately, patients with secondary MDS/AML did not show significant differences in the type of karyotype aberrations compared to de novo MDS or elderly AML (Table 3) . Further analogies included the low incidence of reciprocal translo- Chi-square analysis: young AML vs others: P Ͻ 0.001.
Table 6
Frequency of 5−/del(5q) and 7−/del(7q) among the cytogenetic abnormalities observed in the four groups of patients cations, accounting for 12.5% of chromosomal aberrations, and the frequency of chromosomes 5 and 7 abnormalities, which occurred in a high proportion of patients, 29% and 35%, respectively. Trilineage dysplasia at AML diagnosis was found in six Leukemia cases among 'young AML' (10%), whose median age was 61.5 years, and in 14 cases among 'old AML' (29%). Their frequency of different karyotype aberrations was similar to that of patients with MDS or 'old AML' (Table 3) . Noteworthy, the frequency of normal karyotypes among patients with secondary AML/MDS or with AML with trilineage dysplasia was Ͻ20%, the lowest among all subgroups of patients considered.
Discussion
In this population-based study of patients with MDS and AML, cytogenetic analysis was performed in 80% of cases and was evaluated in 74% of all consecutive patients aged Ͻ86 years.
In patients with MDS (66%) and in elderly AML (71%), the frequency of karyotype abnormalities detected was higher than previously reported. 3, 10, 18, 19 The origin of the present series of patients, which was seen at a primary referral hematologic center, as well as the high proportion of consecutive patients in which cytogenetic studies were performed, may partially explain these discrepancies. It is likely that a higher proportion of older patients with advanced MDS or AML, in which the frequency of abnormal karyotypes is higher, 20 may have been studied in the present series than in series analyzed at referral hematologic centers or in cooperative studies. 21 The profile of cytogenetic abnormalities in young AML markedly differed from all other groups, because of the higher incidence of normal karyotypes and of single cytogenetic abnormalities, and of the pattern of specific chromosome involvement, particularly the low frequency of chromosome 5 and 7 abnormalities. Moreover, young AML had the highest frequency of reciprocal translocations compared to numerical abnormalities. Similar results have been reported in most cytogenetic studies of de novo AML occurring in younger patients. 1, 19, 22 Indeed, a cytogenetic picture of young AML is emerging, characterized by simple and disease-specific changes, referred to as primary cytogenetic abnormalities, which are considered typical of those neoplasias in which the chromosomal changes may play a direct role in tumor initiation. 7 On the other hand, the spectrum of cytogenetic aberrations of all groups other than young AML, showed marked similarities. Complex karyotypes were most frequent, whereas single abnormalities were rare, and chromosomes 5 and 7 were more frequently involved. Moreover, numerical abnormalities largely outweighed reciprocal translocations. In particular, the frequency of the different types of karyotype aberrations found in 'late MDS' and 'old AML' were very similar, suggesting a close cytogenetic relationship between the two entities. The only cytogenetic feature distinguishing the two groups was the number of chromosomes involved in complex karyotypes, which was higher in 'old AML'.
The type of cytogenetic abnormalities in 'early MDS' was also similar to that occurring in 'late MDS' and 'old AML', but the frequency of complex karyotypes as well as the number of chromosomes involved in such cases was lower. However, when CMML was excluded from 'early MDS', the pattern of karyotype aberrations also became similar between 'early MDS' and 'late MDS'. Thus, a sequence of increasing, predominantly numerical, cytogenetic aberrations seemed to link 'early MDS', to 'late MDS' and to 'old AML', with a progressive rise in the frequency of complex vs normal karyotypes, as well as in the number of chromosomes involved in complex karyotypes. The types of chromosomal changes were other-wise very similar, particularly the preferential involvement of chromosomes 5 and 7.
The incidence of secondary AML/MDS was limited in the present series, and did not therefore allow for a meaningful comparison between secondary and de novo MDS/AML. Nevertheless available data were similar to those observed in other series, 13, 23 showing a spectrum of cytogenetic abnormalities in secondary AML/MDS, which shared the same general features found in 'early MDS', 'late MDS' and 'old AML'. The incidence of normal karyotypes was particularly low in secondary AML/MDS. The same characteristics were also shown by cases of AML with trilineage dysplasia at diagnosis. This condition frequently occurs in elderly AML and may represent cases of AML developed from a pre-existing but unrecognized MDS. Its cytogenetic similarity with secondary AML/MDS has already been reported. 24 The cytogenetic picture of CMML in our study substantially differed from other types of MDS. In CMML, cytogenetic abnormalities were reported in 25-30% of cases and important differences compared to other types of MDS were already noted, particularly a low incidence of del 5q. 18 The high frequency of normal karyotypes, together with the very low incidence of complex aberrations in our study clearly distinguished CMML from other types of MDS. These cytogenetic observations would therefore support the concept that a substantial proportion of CMML shares more similarities with the myeloproliferative rather than with the myelodysplastic syndromes. The specificity of CMML among MDS is further supported by recently reported clonality analysis studies, which showed that in CMML the clonal involvement was predominantly limited to the myeloid series, whereas in MDS a pluripotent stem cell was more likely involved. 25, 26 Taken together our results show a close cytogenetic analogy between de novo MDS, particularly RA/RARS, RAEB and RAEB-T, and AML of elderly people, suggesting a common etiopathogenetic mechanism for these conditions. It may be hypothesized that they may indeed represent the same disease entity seen at a different stage of evolution. The continuous occurrence with time, of additions or deletions of chromosomes or part of them, together with the preferential involvement of chromosomes 5 and 7, may create the cytogenetic substrate for the expansion of clones of blast cells leading to the hematologic progression from early myelodysplasia to overt leukemia. Such hypotheses would be clearly strengthened if they were confirmed by future comparative studies, focusing on molecular abnormalities occurring in myelodysplasia and elderly AML.
Since 'secondary' AML also resembles, both cytogenetically and biologically, AML of elderly people, 13 it may be further hypothesized that the same factors responsible for the development of secondary leukemia, such as ionizing radiation or environmental agents, which may be operative throughout life at a very low background level, may be involved in the pathogenesis of de novo MDS as well and that, with increasing age, they may ultimately lead to the development of overt AML in elderly people.
